Denali Therapeutics Inc. (DNLI) Stock Overview
Explore Denali Therapeutics Inc.’s financial performance, market position, analyst ratings, and future outlook.
Denali Therapeutics Inc. (DNLI)
Key Financials
Key Financials
Market Cap
3.8B
P/E Ratio
-8.40
EPS (TTM)
$-2.88
ROE
-0.52%
DNLI Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Denali Therapeutics Inc. (NASDAQ: DNLI) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Denali Therapeutics Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of DNLI on the NASDAQ shows an RSI of 52.28, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $21.99 for the NASDAQ listing.
Key metrics behind Denali Therapeutics Inc.'s NASDAQ-traded stock include a P/E ratio of -8.40 and a market capitalization of 3.8B. Combined with our AI analysis, these give both institutional and retail investors a clear view of DNLI on the NASDAQ.